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ABSTRACT
Objectives To assess the performance of a panel of
common single nucleotide polymorphisms (genotypes)
associatedwithtype2diabetesindistinguishingincident
cases of future type 2 diabetes (discrimination), and to
examine the effect of adding genetic information to
previously validated non-genetic (phenotype based)
models developed to estimate the absolute risk of type 2
diabetes.
Design Workplace based prospective cohort study with
three 5 yearly medical screenings.
Participants 5535 initially healthy people (mean age
49 years; 33% women), of whom 302 developed new
onset type 2 diabetes over 10 years.
OutcomemeasuresNon-geneticvariablesincludedintwo
established risk models—the Cambridge type 2 diabetes
risk score (age, sex, drug treatment, family history of type
2 diabetes, body mass index, smoking status) and the
Framingham offspring study type 2 diabetes risk score
(age, sex, parental history of type 2 diabetes, body mass
index, high density lipoprotein cholesterol, triglycerides,
fasting glucose)—and 20 single nucleotide
polymorphisms associated with susceptibility to type 2
diabetes. Cases of incident type 2 diabetes were defined
onthebasisofastandardoralglucosetolerancetest,self
report of a doctor’s diagnosis, or the use of anti-diabetic
drugs.
Results A genetic score based on the number of risk
alleles carried (range 0-40; area under receiver operating
characteristics curve 0.54, 95% confidence interval 0.50
to 0.58) and a genetic risk function in which carriage of
risk alleles was weighted according to the summary odds
ratiosoftheireffectfrommeta-analysesofgeneticstudies
(area under receiver operating characteristics curve 0.55,
0.51 to 0.59) did not effectively discriminate cases of
diabetes. The Cambridge risk score (area under curve
0.72, 0.69 to 0.76) and the Framingham offspring risk
score (area under curve 0.78, 0.75 to 0.82) led to better
discrimination of cases than did genotype based tests.
Adding genetic information to phenotype based risk
models didnot improvediscriminationandprovidedonly
a small improvement in model calibration and a modest
net reclassification improvement of about 5% when
added tothe Cambridgerisk scorebut not whenadded to
the Framingham offspring risk score.
Conclusion The phenotype based risk models provided
greaterdiscriminationfortype2diabetesthandidmodels
based on 20 common independently inherited diabetes
risk alleles. The addition of genotypes to phenotype
based risk models produced only minimal improvement
in accuracy of risk estimation assessed by recalibration
and, at best, a minor net reclassification improvement.
Themajortranslationalapplicationofthecurrentlyknown
common, small effect genetic variants influencing
susceptibilitytotype2diabetesislikelytocomefromthe
insight they provide on causes of disease and potential
therapeutic targets.
INTRODUCTION
Around one in 10 middle aged Europeans develop
type 2 diabetes over a 10 year period.
1 This may rise
withthethreatenedepidemicoftype2diabetes,driven
partly by the increase in obesity, which is projected to
result in a prevalence of type 2 diabetes worldwide of
366 million by 2030 (www.who.int/diabetes/facts/
world_figures/en/).
2 This will place a considerable
burden on healthcare systems, as type 2 diabetes is a
common cause of renal failure and blindness and
increases the risk of cardiovascular diseases and
mortality.
Estimation of people’s absolute risk of coronary
heart disease, based on the Framingham, PROCAM,
and QRISK equations,
3-5 has become established as a
meansof targetingpreventiveinterventions to thoseat
highest risk. Earlier risk functions for estimating the
risk of type 2 diabetes required an oral glucose toler-
ancetest,whichisimpracticalforscreeninglargenum-
bers of people. Despite evidence that some
interventions prevent or delay development of type 2
diabetesinpeopleathighrisk,
6thepredictionofriskof
new onset type 2 diabetes has not been part of routine
clinical practice.
Two risk scores were published in 2007 and 2008.
They were based on demographic, anthropometric,
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tion from an oral glucose tolerance test. The Cam-
bridge type 2 diabetes risk score is a pragmatic
algorithm incorporating the routinely assessed vari-
ables age, sex, drug treatment, family history of type
2 diabetes, body mass index, and smoking status.
7 In
validating this risk score in the EPIC-Norfolk study,
Rahman et al reported that the model performed well
in distinguishing cases of later type 2 diabetes (discri-
mination), with an area under the receiver operating
characteristics curve of 0.75 (where 1 indicates perfect
discrimination and 0.5 indicates no discrimination).
7
The Framingham offspring type 2 diabetes risk score
also makes use of routinely collected clinical data and
biochemical measures including age, sex, parental his-
tory of type 2 diabetes, body mass index, high density
lipoprotein cholesterol, triglycerides, and fasting glu-
cose. This model also provided good discrimination
of incident cases of diabetes, with an area under the
receiveroperatingcharacteristics curve of0.85.
8 Nota-
bly, the addition of other non-routinelycollected mea-
sures of glucose metabolism such as the homoeostasis
modelassessment,fastinginsulin,ortwohouroralglu-
cosetolerancetestdidnotimprovetheriskprediction.
8
Both risk algorithms include information on family
history of type 2 diabetes. However, family history
reflects shared environment as well as genotype, and
whereas biochemical and non-biochemical features
associated with type 2 diabetes alter with age, genetic
predisposition is determined at conception and fixed
through life. Identifying genotypes that alter suscept-
ibility to type 2 diabetes, and using them on their own
or in combination with existing phenotype based risk
algorithms,mightthereforeimprovepredictionofrisk,
particularly if genotypes identify differences in the
activity of pathways unmeasured in non-genetic risk
models.
Large case-control studies using whole genome
arrays of single nucleotide polymorphisms (genome-
wideassociationstudies)haveidentifiedmultiplecom-
mon risk alleles for type 2 diabetes, many of which
reside in or near genes not previously implicated in
thepathogenesisofdiabetes,
9-12inadditiontoconfirm-
ing loci identified by previous candidate gene
studies.
1314 Around 20 single nucleotide poly-
morphisms associated with type 2 diabetes have been
identified, for which the findings from the discovery
study have been independently replicated in addi-
tional datasets and the effect sizes evaluated precisely
bymeta-analysis(asdetailedinwebtableA).
15-18Forall
loci identified to date, effect sizes have been modest,
with odds ratios for risk of type 2 diabetes ranging
from 1.37 for single nucleotide polymorphisms in the
geneTCF7L2to1.09forthoseinthegeneADAMTS9,
18
raising the question of whether information on geno-
type would be useful for prediction of risk. Moreover,
risk alleles have been discovered mainly by using
case-control studies, which, although efficient for the
discovery of disease associated single nucleotide poly-
morphisms,aresuboptimalforevaluatingtheirperfor-
mance as predictors of risk. This is optimally assessed
by genotyping the genetic markers in prospective stu-
dies of initially healthy people in whom cases of inci-
dent disease accrue over time. However, the study
designs, the number of disease associated single
nucleotide polymorphisms evaluated, the metrics
usedtoevaluatepredictiveperformance,andthemeth-
odsusedtocomparetheperformanceofgenotypewith
non-genetic risk factors have been variable. Despite
this, genetic tests for the prediction of type 2 diabetes
have already become available in the commercial sec-
tor (for example, www.23andme.com and www.deco
deme.com/).
In this study, we first compared the ability of two
phenotype based risk algorithms, the Cambridge risk
score and the Framingham offspring risk score,
78with
genotype based risk models for the discrimination of
incident cases of type 2 diabetes in the prospective
Whitehall II studyof civil servants in the United King-
dom.We then evaluatedthe effect of addition of geno-
types to the two non-genetic risk algorithms on the
ability to discriminate between people who developed
type 2 diabetes and those who remained free of the
disease. We further assessed the effect of adding geno-
type to the calibration of the risk models (which
involves assessing the closeness of the observed event
rate to the predicted risk in different risk categories) as
well as reclassification (which assesses the extent to
which addition of genetic information shifts people to
categories of predicted risk that better reflect their
eventual outcome).
19
METHODS
Study population
Between 1985 and 1988, all civil servants aged
between 35 and 55 years in 20 departments in central
Londonwereinvitedtoa medicalexaminationattheir
workplace.
2021 With 73% participation, the cohort
included 10308 participants at entry to the study. At
phase 3 in 1991-3, all participants known to be alive
and in the country were invited to the screening clinic,
which included an oral glucose tolerance test; 6058
men and 2758 women (85.5% of the original sample)
attended. For this analysis, phase 3 (when an oral glu-
cosetolerancetestwasdoneforthe firsttime)servesas
the baseline. Biochemical screening was repeated at
phase 5 (1997-9) and phase 7 (2003-4). Additional
questionnaire-only phases assessed diabetes status at
phase 4 (1995-6) and phase 6 (2001). Of the baseline
participants, 6156 participated in phase 7 screening, at
which DNA was collected.
Clinical characteristics
Wemeasuredage,sex,bodymassindex,waistcircum-
ference, blood pressure, lipids, C reactive protein,
fibrinogen, glucose, smoking, and coronary heart dis-
ease and diabetes status at baseline. Weight was mea-
sured in underwear to the nearest 0.1 kg on Soehnle
electronic scales. We measured height in bare feet to
the nearest 1 mm by using a stadiometer with the par-
ticipantstandingerectwithheadintheFrankfortplane.
Wecalculatedbodymassindexasweight(kilograms)/
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ference, taken as the smallest circumference at or
below the costal margin, with participants unclothed
in the standingposition by using a fibreglass tape mea-
sureat600gtension.Wemeasuredsystolicbloodpres-
sure and diastolic blood pressure twice in the sitting
positionafterfiveminutes’restwiththeHawksleyran-
dom zero sphygmomanometer. We took the average
ofthe tworeadingstobethemeasuredbloodpressure.
Wetookvenousbloodinthefastingstateoratleastfive
hours after a light, fat free breakfast, before a two hour
75 g oral glucose tolerance test was done. Serum for
lipid analyses was refrigerated at −4°C and assayed
within72hours.WeusedaCobasFaracentrifugalana-
lyser (Roche Diagnostics System, Nutley, NJ) to mea-
sure cholesterol and triglyceride concentrations. We
measured high density lipoprotein cholesterol by pre-
cipitating non-high density lipoprotein cholesterol
with dextran sulfate-magnesium chloride with the use
of a centrifuge and measuring cholesterol in the super-
natant fluid. We used the Friedewald formulato calcu-
late low density lipoprotein cholesterol concentration.
We measured C reactive protein in serum stored at
−70°C with a high sensitivity immunonephelometric
assay in a BN ProSpec nephelometer (Dade Behring,
Milton Keynes). We measured fibrinogen by an auto-
mated Clauss assay in an MDA-180 coagulator (Orga-
non Teknika, Cambridge), using the manufacturer’s
reagents and the international fibrinogen standard.
We measured blood glucose by the glucose oxidase
method on a YSI Model 23A glucose analyser,
2223
and serum insulin with an in-house human insulin
radioimmunoassay.
24 We defined prevalent coronary
heart disease as meeting MONICA criteria,
25 giving
positiveresponsestoquestionsaboutchestpain,
26phy-
sician’s diagnosis, evidence from medical records, or
positive electrocardiographic findings.
Diabetes, HbA1c, and homoeostasis model assessment
Wedetermineddiabetesstatusonthebasisofa75goral
glucose tolerance test (phases 3, 5, and 7), use of anti-
diabetic drugs, or self report of a doctor’s diagnosis
(phases 3 to 7). We defined diabetes by a two hour glu-
coseofatleast11.1 mmol/l orfasting glucose ofatleast
7 mmol/l.
27 Glycated haemoglobin (HbA1c)w a sm e a -
sured at phase 7 in EDTA whole blood on a calibrated
HPLCsystem with automated haemolysisbefore injec-
tion. HbA1 is resolved as a separate peak, which does
not interfere with quantification of HbA1c.
28 We calcu-
latedhomoeostasismodelassessmentas(fastingglucose
(mmol/l) × fasting insulin (mU/l)/22.5).
29 Non-fasting
participants (fasting less than five hours) were assigned
a missing value (n=435, 9.1%).
Genotyping
WeextractedDNAfrombloodsamplesbyusingmag-
netic bead technology (Medical Solutions, Notting-
ham). Medical Solutions used SNPLex (Applied
Biosciences) to determine the following single nucleo-
tide polymorphisms, chosen because their association
withdiabetesriskhasbeenreplicatedandtheeffectsize
has been estimated with precision from large scale
meta-analysis (web table A): ADAMTS9 rs4607103,
CALPN10 rs3792267, CDC123 (CAMK1D)
rs12779790, CDKN2B rs10811661, FTO rs1421085
(which is complete LD with rs9930506
30), HHEX
rs1111875, HNF1A (TCF2) rs1800574, IGF2BP2
rs440296, JAZF1 rs864745, KCNJ11 rs521, NOTCH2
rs10923931, PPARG rs1801282, SLC30A8
rs13266634, TCF2(HNF1B) rs4430796, TCF7L2
rs12255372, THADA rs7578597, and TSPAN8
(LGR57) rs7961581. Single nucleotide poly-
morphisms in BCL11A rs10490072, CDKAL1
rs17036101, TCF7L2 rs7901695, and VEGFA
rs9472138 were genotyped by using the 50K IBC
CVD chip (web table B).
31 All single nucleotide poly-
morphisms were in Hardy-Weinberg equilibrium (χ
2,
P>0.05).
Statistical analysis
We used two sample t tests to compare mean baseline
values of continuous variables in people who devel-
opeddiabetesandthosewhodidnot.Whereappropri-
ate, we log transformed variables and present
geometric means and approximate standard devia-
tions. We used the χ
2 test to compare categorical vari-
ables. We assessed the association of each genotype
with risk of diabetes by logistic regression analysis
and summarised the data by odds ratios and 95% con-
fidenceintervals.Weusedpublishedregressioncoeffi-
cients to calculate the Cambridge type 2 diabetes risk
score and Framingham offspring study type 2 diabetes
risk score for each participant.
78In addition, we calcu-
lated two genetic scores. In the first, we assigned each
person a score based simply on the number of risk
alleles carried. Thus for CDKAL1, CDC123/
CAMK1D, FTO, HNF1A, IGFBP2, KCNJ11, NOTCH2,
TCF2, TCF7L2, TSPAN8/LRG5, and VEGFA,w e
coded genotypes “0” for common allele
homozygotes,
11 “1” for heterozygotes, and “2” for
rare allele homozygotes,
22 and for ADAMTS9,
BCL11A, CALPN10, CDKN2A/2B, HHEX, JAZF1,
PPARG, SLC30A8, and THADA, coding was “2” for
common allele homozygotes and “0” for rare allele
homozygotes,
11 as the rare allele is reported to be pro-
tective(seewebtableB).Inthesecondscore,wecalcu-
lated a genetic risk function by using weights derived
from the risk coefficient for each gene based on odds
ratios reported in previous meta-analyses (web table
A).
15161832 Risk estimatesforeach allele were available
for 18 genes, and we multipliedthese coefficientsby 0,
1,or2accordingtothenumberofriskallelescarriedby
each person. Where effect estimates were reported for
carriageofeitheroneortwocopiesofeachriskalleleas
a single group (CALPN10 and HNF1A), we multiplied
risk coefficients by a score of 0 or 1. We assumed
genetic and clinical variables to be independent and
added the weighted genetic score to each of the risk
algorithms to provide a combined phenotypic and
genetic score.
We assessed discrimination with the detection rate,
which is equivalent to sensitivity and defined as the
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positive rate, as well as the area under the receiver
operating characteristics curve. We assessed the cali-
bration of the Cambridge risk score and Framingham
offspring risk score in the estimation of the absolute
risk of type 2 diabetes by comparing the difference
betweenobservedandexpectedeventratesindifferent
categories of risk with the Hosmer-Lemeshow test,
with Akaike’s information criterion and the likelihood
ratiotestasglobalmeasuresofmodelfit.
33Weusedthe
netreclassificationimprovementmeasuretoassessthe
extenttowhichaddingthegeneticvariablesreassigned
peopletoriskcategoriesthatbetterreflectedtheirfinal
outcome.
34
RESULTS
Web table C shows the baseline characteristics of the
study participants. We excluded 103 people with pre-
valenttype2diabetesatbaselinefromsubsequentana-
lysis.Ofthe5135participantsfollowedforamedianof
11.7 years to phase 7, with complete phenotype and
genotypemeasures,302haddevelopedtype2diabetes
by phase 7.
Discrimination using phenotype based risk scores
The odds ratio for developing diabetes was 8.4 (95%
confidence interval 5.1 to 13.9) for people in the top
fifth of the Cambridge risk score distribution com-
pared with those in the bottom fifth, and the area
under the receiver operating characteristics curve was
0.72 (95% confidence interval 0.69 to 0.76) at phase 7
(table 1). The odds ratio for type 2 diabetes in partici-
pants in the top fifth of the Framingham offspring risk
score distribution compared with those in the bottom
fifth was 18.2 (9.8 to 33.8), with a significantly greater
area under the receiver operating characteristics curve
of0.78(0.75to0.82)(P=0.01)(table 1andfig1).Detec-
tion rates (sensitivity) for a 5% false positive rate were
19.7 (95% confidence interval 14.1 to 25.3) for the
Cambridge risk score (cut-off point 0.34) and 30.6
(24.1 to 37.1) for the Framingham offspring risk score
(cut-offpoint0.08).Therespectivedetectionratesfora
10% false positive rate were 34.2 (27.5 to 40.9; cut-off
point 0.26) and 43.0 (36.0 to 50.0; cut-off point 0.05)
(table 1).
Discrimination using genotype based risk scores
Web table B shows details of the 20 single nucleotide
polymorphisms typed, together with risk estimates for
type 2 diabetes from published meta-analyses (web
tableA). Allgenotypeswere in Hardy-Weinbergequi-
librium. In line with previous reports, FTO rs1421085
was associated with body mass index (P<0.001).
30
CDC123/CAMK10 rs10811661 (P=0.001), KCNJ11
rs5219 (P<0.01), and TCF7L2 rs7901695 (P<0.002)
were associated with two hour glucose after an oral
glucose tolerance test. CALPN10 rs3792267 was asso-
ciated with significant differences in concentrations of
total cholesterol and low density lipoprotein choles-
terol (P=0.01). We found no other associations
between genotypes and phenotypes included in either
of the non-genetic risk models at phase 3 or phase 7
(web tables D-J). The point estimates of the effect
sizes were consistent with previous meta-analyses
involving many thousands of cases of type 2 diabetes
(web table A). However, as would be expected in a
prospective study with fewer cases of diabetes and in
agreementwiththepreviousreportfromaprospective
study of similar size,
35 most associations were not sig-
nificant at P<0.05 in this dataset.
Figure 2 shows the distribution of the gene count
score in people who developed type 2 diabetes and
those who remained free of diabetes; the web figure
shows the equivalent data for genetic risk function.
Fourteen per cent of people with type 2 diabetes were
in the top fifth of the gene count score compared with
13.9% of those without type 2 diabetes (web table K).
Theoddsratiofortype2diabetesforparticipantsinthe
topfifthofthescorewas1.6(0.9to2.5)comparedwith
those in the bottom fifth. Twenty-five per cent of peo-
ple with type 2 diabetes were in the top fifth of the
genetic risk function, compared with 20% of those
without diabetes, giving an odds ratio for type 2 dia-
betes of 2.3 (1.5 to 3.8) (web table K). The mean gene
count score was 21.1 (SD 2.6) in people with type 2
diabetesand20.5(2.7)inthosewithouttype2diabetes
(web table K). The simple gene count and the genetic
risk function gave very similar discrimination, with
areas under the receiver operating characteristics
curve of 0.54 (0.50 to 0.58) (fig 1) and 0.55 (0.51 to
0.59) (table 1). Table 1 shows the detection rates at
5% and 10% false positive rates.
Effect of adding genetic information to discrimination and
calibration of risk models
The addition of genetic information to either of the
phenotype based risk models (using the simple gene
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Fig 1 | Receiver operating characteristics curves for gene count
score alone (area under curve 0.54, 95% CI 0.50 to 0.58),
Framingham offspring risk score (area under curve 0.78, 0.75
to 0.82), and gene count score incorporated into Framingham
offspring risk score (area under curve 0.78, 0.75 to 0.81)
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crimination (table 1). Because part of the information
included in the family history component of a risk
score could reflect carriage of common genotypes,
this may have undermined the incremental value of
genetic information for predicting risk. However, the
variants we studied explain only a small proportion of
the familial aggregation of diabetes, and a formal ana-
lysisoftheeffectofinclusionorexclusionofthefamily
historyvariablehad almostnoeffectonthe area under
thereceiveroperatingcharacteristicscurve(dataavail-
able on request).
36
The additionof genetic informationdid little toalter
the accuracy of the phenotype based models when
assessed with the Hosmer-Lemeshow test of calibra-
tion (table 2). Although the improvement in fit of the
modelwasstatisticallysignificantwhentheCambridge
risk score was supplemented by the genetic risk func-
tion, the magnitude of the change was very small and
unlikely to have any worthwhile clinical impact.
We generated four 10 year risk categories for type 2
diabetesforeachofthetwophenotypebasedriskmod-
els (≤5%, 5-9.9%, 10-14.9%, and ≥15%) and then com-
pared the observed and predicted event rates in each
categoryofrisktoassessiftheadditionofgeneticinfor-
mation improved calibration (that is, the closeness of
the observed event rate to the predicted risk) (table 3).
Thephenotypebasedriskmodelsaccuratelyestimated
the rates of diabetes in each of the four categories of
predicted risk.
Reclassification
We used the net reclassification index to assess the
extenttowhichaddinggenotypedatatothephenotype
based risk models resulted in the movement of partici-
pantsintoriskcategoriesthatmoreaccuratelyreflected
their eventual outcome. In these analyses, we used the
same four risk categories (≤5%, 5-9.9%, 10-14.9%, and
≥15%) and did the analyses separately for people diag-
nosedashavingtype2diabetesonfollow-upandthose
who remained healthy. Among the eventual cases, a
shifttoahigherriskcategoryontheadditionofgenetic
informationisclassedasacorrectreclassificationanda
downward shift as an incorrect reclassification. The
opposite is the case for people who remained healthy.
The addition of the simple gene count to the Cam-
bridge risk score resulted in a net reclassification
improvement of −1.1% (95% confidence interval
−6.0% to 3.8%) (table 4), and the addition of informa-
tion from the genetic risk function produced a net
reclassification improvement of 4.6% (−2.0% to
11.3%) (P=0.17) (web table L). Neither the simple
gene count score (net reclassification improvement
0.2%,−5.1to4.7)(table 5)northegeneticriskfunction
(net reclassification improvement −3.2%, −9.9 to 3.5)
(web table M) resulted in a net reclassification
improvement when added to the Framingham off-
spring risk score.
Table 1 |Odds ratios and area under receiver operating characteristics curve for Cambridge type 2 diabetes risk score, Framingham offspring type 2 diabetes
risk score, and genetic risk scores alone and in combination in Whitehall II study
Risk model Odds ratio* (95% CI)
Area under receiver
operating characteristics
curve (95% CI)
Detection rate for 5% false
positive rate
Detection rate for 10% false
positive rate
Cambridge risk score 8.4 (5.1 to 13.9) 0.72 (0.69 to 0.76) 19.7 (14.1 to 25.3) 34.2 (27.5 to 40.9)
Framingham offspring risk score 18.2 (9.8 to 33.8) 0.78 (0.75 to 0.82) 30.6 (24.1 to 37.1) 43.0 (36.0 to 50.0)
Gene count score 1.7 (0.9 to 2.5) 0.54 (0.50 to 0.58) 6.5 (3.5 to 10.8) 9.9 (6.2 to 14.9)
Genetic risk function score 2.3 (1.5 to 3.8) 0.55 (0.51 to 0.59) 6.4 (3.5 to 10.8) 11.4 (7.4 to 16.6)
Cambridge risk score and gene count score 9.7 (5.4 to 17.4) 0.73 (0.69 to 0.76) 20.3 (15.0 to 26.5) 33.7 (27.2 to 40.6)
Cambridge risk score and genetic risk function score 7.9 (4.5 to 13.7) 0.73 (0.69 to 0.76) 21.8 (16.3 to 28.1) 32.2 (25.8 to 39.1)
Framingham offspring risk score and gene count score 11.2 (6.1 to 20.5) 0.78 (0.75 to 0.81) 29.7 (23.5 to 36.5) 42.6 (35.7 to 49.7)
Framingham offspring risk score and genetic risk function score 11.0 (6.0 to 20.1) 0.78 (0.74 to 0.81) 31.2 (24.9 to 38.1) 40.1 (33.3 to 47.2)
*Odds ratio for top versus bottom fifth.
Gene count score
P
e
r
c
e
n
t
a
g
e
10 15 20 25 30
0
4
8
12
16
20
Type 2 diabetes Type 2 diabetes-free
Fig 2 | Percentage of participants in each gene count score
category among those who developed type 2 diabetes and
those who remained free from diabetes. Risk of developing
diabetes according to gene count shown as fitted line from
regression analysis
Table 2 |Effect of adding genetic information to global model fit and calibration of risk
models to examine indices of model fit
Risk model
Hosmer-
Lemeshow P
value
Akaike’s
information
criterion
Likelihood ratio
test P value
Cambridge risk score 0.77 1416.1 NA
Framingham offspring risk score 0.42 1319.7 NA
Cambridge risk score plus gene count score 0.85 1414.9 0.07
Framingham offspring risk score plus gene count score 0.52 1319.7 0.17
Cambridge risk score plus genetic risk function score 0.50 1413.4 0.03
Framingham risk score plus genetic risk function score 0.55 1318.9 0.10
NA=not applicable.
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In a British cohort (the Whitehall II study), a panel of
20 genotypes associated with type 2 diabetes per-
formedlesswellthantheCambridgeandFramingham
offspring type 2 diabetes risk scores in discriminating
incident cases of type 2 diabetes. Adding the genetic
panel to the phenotype based risk models did not
improve discrimination and produced only minimal
improvement in accuracy of risk estimation assessed
by recalibration and, at best, a minor net reclassifica-
tion improvement.
Over the past five years, the pace of identification of
genetic loci underlying susceptibility to common dis-
eases has increased rapidly, leading to interest in how
this information might best be used to improve perso-
nal and public health. One potential application is the
useofgeneticinformationtohelppredictsusceptibility
todiseaseininitiallyhealthy people,soastofocuspre-
ventive interventions on those at the highest risk of
future disease. This targeted approach to prevention
is exemplified by the established use of risk equations
based on non-genetic variables to estimate risk of cor-
onaryheartdiseaseandguidebloodpressurelowering
andcholesterolloweringtreatment.
34Thisapproachto
thepreventionofvasculardisease,forwhichdiabetesis
a majorriskfactor,will becomemoresystematicinthe
next two years, through the Department of Health’s
vascular health check scheme (www.dh.gov.uk/en/
Publicationsandstatistics/Publications/PublicationsPo
licyAndGuidance/DH_083822).
Preventive interventions also exist for type 2 dia-
betes, which motivated the recent evaluation of risk
scores(includingthose studiedhere)forthe prediction
of type 2 diabetes. The Cambridge risk score and the
Framingham offspring risk score are based on a com-
bination of demographic, family history, anthropo-
metric, and biochemical data, but neither includes
genetic information.
78 Although these phenotype
based risk models seem to perform well, an important
question is whether typing a panel of validated genetic
riskfactorsmightimprovetheirabilitytopredicttype2
diabetes.Some studiesin this area have usedcase-con-
troldatasets.
37-39Althoughefficientforgenediscovery,
theseareasuboptimaldesignforevaluatingthepredic-
tive performance of a marker, as risk information is
availableonlyinrelativetermsandtherangeofmetrics
that can be derived to assess predictive performance is
morelimitedthanforprospectivestudieswithincident
cases of disease. Those prospective studies that have
previously evaluated the performance of genetic mar-
kers have been set outside the UK, typed fewer type 2
diabetesriskalleles,orreportedonlysomeofarangeof
metrics available to evaluate the performance of a pre-
dictivetest (table 6).
3540-42 In a prospective studysetin
theUK,wethereforetestedtheperformanceofapanel
of 20 common genes associated with type 2 diabetes,
Table 3 |Prevalence and percentage of incident cases of type 2 diabetes in categories of predicted risk calculated by using
phenotype based risk models alone, and same models with addition of genetic data
Category of predicted risk Proportion
reclassified (%) <5% 5-9.9% 10-14.9% >15%
Cambridge risk score
Without genotype scores 64/2257 (2.8) 54/753 (7.2) 48/328 (14.6) 36/188 (19.2) NA
With simple gene count score 63/2226 (2.8) 59/787 (7.5) 41/317 (12.9) 39/196 (19.9) 322/3526 (9.9)
With genetic risk function 57/2191 (2.6) 61/824 (7.4) 42/309 (13.6) 42/202 (20.8) 522/3526 (16.0)
Framingham offspring risk score
Without genotype scores 60/2403 (2.5) 42/603 (7.0) 31/261 (11.9) 69/259 (26.6) NA
With simple gene count score 54/2385 (2.3) 49/598 (8.2) 32/265 (12.1) 67/278 (24.1) 210/3526 (6.0)
With genetic risk function 55/2381 (2.3) 54/614 (8.8) 26/255 (10.2) 67/276 (24.3) 432/3526 (12.3)
NA=not applicable.
Table 4 |Net reclassification improvement based on addition of gene count score to Cambridge risk score
Predicted diabetes risk
(Cambridge risk score)
No of people Reclassified Net correctly
reclassified
(%) <5% 5-10% 10-15% >15%
Increased
risk
Decreased
risk
Plus gene count score— —people without diabetes during follow-up (n= =3324)
<5% 2088 105 0 0
167 131 −1.1
5-9.9% 75 581 43 0
10-14.9% 0 42 219 19
≥15% 0 0 14 138
Plus gene count score— —people with diabetes during follow-up (n= =202)
< 5 % 6 0 400
12 12 0
5-9.9% 3 49 2 0
10-14.9% 0 6 36 6
≥15% 0 0 3 33
Net reclassification improvement −1.1% (95% CI −6.0% to 3.8%); P=0.66.
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the risk of type 2 diabetes, and compared prediction
based on genetic information alone, phenotypic infor-
mation alone, and both, by using a range of metrics to
assess predictive performance.
We found that risk functions based on routinely
measured clinical variables better discriminated inci-
dent type 2 diabetes cases than did a panel of 20 dia-
betes associated single nucleotide polymorphisms.
Theinclusionofgeneticinformationintheriskmodels
did not improve the discrimination of cases of type 2
diabetes, and nor did it provide clinically important
improvement in the accuracy of these models when
assessed by calibration. The addition of genetic data
tophenotypebasedriskmodelsalsoprovidedminimal
net reclassification improvement. The addition of
genetic information resulted in the reassortment of
people into different risk categories, but not all the
shifts were helpful. Although some eventual cases
were upgraded to higher risk categories, almost as
many had their risk downgraded, and the opposite
was true for many of those who remained healthy.
Table 6 |Comparison of published studies that have used genetic information with or without non-genetic risk factors to discriminate between people with
and without type 2 diabetes, in case-control, cross sectional, or prospective settings
Study Study design No of cases Non-genetic risk factors Noofriskallelesstudied
Other metrics of prediction
reported
Including Diabetes UK Warren 2
repository and people with early
onset type 2 diabetes and 1958
birth cohort as controls
44
Case-control 2406 type 2 diabetes, 3668
controls
None 3 None
DESIR
37 Prospective 187 type 2 diabetes, 336
impaired glucose tolerance,
2732 non-type 2 diabetes
Age, sex, body mass index 3 None
DESIR plus DIAB2.NEPHRO-GENE
and people with normal glucose
tolerance from SU.VI.MAX
38
Case-control 4232 type 2 diabetes,
4595 glucose tolerant
Age, sex, body mass index 15 None
Rotterdam Study
39 Prospective 686 type 2 diabetes, 5221 non-
type 2 diabetes
Age, sex, body mass index 18 None
Framingham Offspring Study
35 Prospective 255 type 2 diabetes, 2122 non-
type 2 diabetes
Age, sex, family history of type 2
diabetes, body mass index,
fasting glucose, systolic blood
pressure, triglycerides, high
density lipoprotein cholesterol
18 Net reclassification index
Mälmo Preventive Project and
Botnia Study
40
Prospective 2063 type 2 diabetes, 12 210
non-type 2 diabetes; 138 type2
diabetes, 2632 non-type 2
diabetes
Age, sex, family history of type 2
diabetes, body mass index,
blood pressure, triglycerides,
fasting glucose
16 Integrated discrimination
improvement
GoDARTS41 Case-control 2309 cases, 2598 controls Age, sex, body mass index 18 None
Co-Laus
42 Cross sectional 356 type 2 diabetes, 5004 non-
type 2 diabetes
Age, body mass index, family
history of type 2 diabetes, waist:
hip ratio, triglyceride:high
density lipoprotein cholesterol
ratio, physical activity
15 Integrated discrimination
improvement
Inter99 study, ADDITION study,
plus type 2 diabetes cases and
people with normal glucose
tolerance
43
Cross sectional 4093 type 2 diabetes,
5302 glucose tolerant
Age, sex, body mass index 19 None
See Forrest plots at www.ucl.ac.uk/genetic-epidemiology/WebMaterial.
Table 5 |Net reclassification improvement based on addition of gene count score to Framingham offspring risk score
Predicted diabetes risk
(Framingham offspring
risk score)
No of people Reclassified Net correctly
reclassified
(%) <5% 5-10% 10-15% >15%
Increased
risk
Decreased
risk
Plus gene count score—people without diabetes during follow-up (n=3324)
<5% 2295 48 0 0
121 64 −1.7
5-9.9% 36 482 43 0
10-14.9% 0 19 181 30
≥15% 0 0 9 181
Plus gene count score—people with diabetes during follow-up (n= 202)
< 5 % 5 2 800
14 11 1.5
5-9.9% 2 37 3 0
10-14.9% 0 4 24 3
≥15% 0 0 5 64
Net reclassification improvement 0.2% (95% CI −5.1 to 4.7); P=0.94.
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lished reports of 10 study populations (table 6),
35373840-44
eventhoughthenumber andrange of genotypesandthe
phenotype based risk models used for prediction varied
across studies (see Forrest plots at www.ucl.ac.uk/
genetic-epidemiology/WebMaterial). All models
included age, body mass index, and sex, and much of
the predictive information in any phenotype based
model is likely to be encompassed in these terms.
The relations shown in figure 2 and the web figure
illustrate one reason for the poor predictive perfor-
mance of a panel of single nucleotide polymorphisms
associatedwithcommondiseases.Althoughpeoplecar-
rying multiple risk alleles are at more extreme risk of
type 2 diabetes than those carrying fewer copies, they
represent only a small proportion of the population,
becausetheinheritanceofeachriskalleleisanindepen-
dent event—the probability of inheriting multiple risk
allelesisa functionofthe frequencyofeachalleleinthe
population. For example, the probability of inheriting
10 independent risk alleles with frequenciesaround0.3
is 0.3
10 (about 6×10
−6). People with an intermediate
number of risk alleles would therefore be expected to
accountforthemajorportionofcasesoftype2diabetes,
because of the large number of people at intermediate
risk in the population. This explains the substantial
overlap of the distribution of risk alleles among people
who developed diabetes and those who remained dis-
ease-free,whichmakesitdifficulttosetacut-offpointof
a gene count (or genetic risk function) that reliably dis-
criminates later cases of type 2 diabetes. Although
genetic tests for type 2 diabetes, based on a subset of
the alleles studied here, can already be purchased in
the commercial sector, our findings suggest that much
more rigorous evaluation of their use as a health tech-
nologyisneededbeforesuchtestsshouldbeadoptedby
healthcare organisations.
As a technology, however, genotype based tests
have several inherent advantages over non-genetic
tests.Genotypebasedassaysarecheap,havehighfide-
lity, and can be multiplexed, in contrast to multiple
phenotypic risk factors and biomarkers, many of
which require different methods for their measure-
ment,andwhicharemoreaffectedbybiologicalvaria-
bility and measurement error than is genotyping.
Moreover, because genotype is invariant it offers the
prospect of risk assessment from much earlier in life
than is possible with phenotype based tests. In the
case of cardiovascular risk factors, evidence shows
that greater benefits accrue from earlier intervention
among people at higher risk (for example, in the form
of smoking cessation or cholesterol lowering).
4546 The
findings of our study should thus not lead to the pre-
maturedismissalofgenotypebasedriskpredictionasa
health technology. Rather, increased efforts should be
made to understand the strengths and limitations of
such tests as well as their optimal place in health care,
a conclusion highlighted in the recent House of Lords
ScienceandTechnologyCommittee’sreportongeno-
mic medicine (www.publications.parliament.uk/pa/
ld200809/ldselect/ldsctech/107/107i.pdf).
Limitations of study
Some limitations of our study should be noted.
Although prospective, the Whitehall II study is work-
place based and therefore not necessarily representa-
tive of the general population. However, the excellent
performance in Whitehall II of the non-genetic risk
functionsfortype2diabetes,bothofwhichweredevel-
oped and validated in general populations, suggests
that this is unlikely to bias our conclusions substan-
tially. Moreover, our findings are consistent with
those of prospective studies set in representative gen-
eral populations. Our findings are also not generalisa-
ble to people of non-European ancestry, who we
excluded from this analysis. Although DNA was col-
lected some time after baseline, which could have
introducedasurvivorbias,wethinkthatthisisunlikely
to have affected our results given the modest effect of
the alleles we studied on risk of diabetes and the long
natural history of the development of the life threaten-
ing complications of diabetes.
The two risk tools studied, based on non-genetic
markers, performed better than genotype based tests
despitethefactthatthemodels,whichweredeveloped
in different datasets, were not specifically recalibrated
fortheWhitehallIIpopulation.Thecommondiabetes
associated single nucleotide polymorphisms we stu-
died might have greater incremental value in the pre-
dictionoftype2diabeteswhenevaluatedagainstsome
of the other validated risk models. However, we chose
the Framingham and Cambridge risk scores because
they are contemporary (which could be important,
given the recent increase in the incidence and preva-
lence of type 2 diabetes), were developed in popula-
tions with a similar profile to the Whitehall II
participants, and were based on studies set in the Uni-
ted States and the UK, where many of the genetic stu-
dies were done. Moreover, both include variables that
are routinelymeasuredin clinical practice. We didnot
evaluate QDRisk, which is based on routinely col-
lectedprimarycaredata(includingdeprivationscores,
ethnicity, and current drugtreatment for hypertension
or cardiovascular disease and corticosteroid use),
which was reported during the preparation of this
manuscript.
47
Because part of the information included in the
family history component of a risk score will reflect
common genotypes, this may have undermined the
incremental value of genetic information for risk pre-
diction.However,thevariantswestudiedexplainonly
a small proportion of the familial aggregation of
diabetes.
36Whethergenotypeshavegreaterpredictive
utilityinparticularcategoriesofpatient(suchasamong
leanerpeopleorthoseofaparticularancestry)couldbe
assessed by pooling participant level data from a large
number of prospective studies with the relevant infor-
mationtoensureadequatepower.Ourcurrentanalysis
is limited to the 20 common risk alleles for type 2 dia-
betes identified by large association or genome-wide
studies. However, sequence variants of intermediate
frequency but larger effect size are likely to be uncov-
ered by future research, so our interpretation on the
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interim. Moreover, as the actual causal variants at
each gene/region remain for the most part uncertain,
the predictive utility of genetic markers may also have
been underestimated.
Our conclusions about the performance of genetic
testing for type 2 diabetes are confined to the use of
single common alleles at each locus. Other common
risk alleles are likely to exist at the same genetic loci
(including the causal variants), which could provide
additional information relevant to prediction. Our
conclusionsarealsonottransferrabletoothercommon
diseases. For example, genetic variants underlying the
susceptibilitytoagerelatedmaculardegenerationhave
been identified, at least one of which is both common
and large in its effect on risk.
48 We previously exam-
ined the predictive utility of a common single nucleo-
tidepolymorphismassociatedwiththeriskofcoronary
heart disease at the 9p23.1 chromosomal locus
(rs10757274) when added to a risk function that
included variables incorporated in the Framingham
coronary heart disease risk equation.
49 Although this
genotype added minimally to the ability of the Fra-
mingham risk score to discriminate future events,
improving the area under the receiver operating char-
acteristics curve by only 3%, it did significantly
improve reclassification of risk of coronary heart dis-
ease, albeit modestly. Moreover, for some disorders,
including age related macular degeneration, few if
any non-genetic biomarkers or risk factors exist that
can be used to estimate risk of future disease.
Conclusions
Phenotype based risk models (the Framingham off-
spring and Cambridge risk scores) provided greater
discrimination for type 2 diabetes than did models
based on 20 common independently inherited alleles
associated with risk of type 2 diabetes. The addition of
20 common genotypes associated with modest risk to
phenotype based risk models produced only minimal
improvement in the accuracy of risk estimation
assessedbyrecalibrationandatbestaminornetreclas-
sificationimprovement.Themajortranslationalappli-
cation of the currently known common, small effect
geneticvariantsinfluencingsusceptibilitytotype2dia-
betesislikelytocomefromtheinsighttheyprovideon
causes of disease and potential therapeutic targets.
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